STOK
Stoke Therapeutics, Inc. NASDAQ Listed Jun 19, 2019$31.00
+2.45%
vs $30.26
Mkt Cap $1.8B
52w Low $11.35
72.8% of range
52w High $38.35
50d MA $32.07
200d MA $30.74
P/E (TTM)
—
EV/EBITDA
—
P/B
5.2x
Debt/Equity
0.0x
ROE
-1.9%
P/FCF
40.9x
RSI (14)
50.40
ATR (14)
$1.45
Beta
1.22
50d MA
$32.07
200d MA
$30.74
Avg Volume
613.5K
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
45 Wiggins Avenue · Bedford, MA 01730 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.80 | -0.79 | +1.2% | 32.79 | -2.7% | +0.3% | -0.8% | -0.5% | -2.4% | -1.1% | — |
| Mar 16, 2026 | AMC | -0.75 | -0.97 | -29.3% | 33.96 | -3.2% | -3.2% | -5.6% | +7.0% | +1.0% | -0.3% | — |
| Nov 4, 2025 | AMC | -0.54 | -0.65 | -20.4% | 25.34 | -13.4% | -9.9% | -1.5% | +1.7% | -2.1% | +12.2% | — |
| Aug 12, 2025 | AMC | -0.57 | -0.40 | +29.8% | 13.53 | +10.1% | +25.0% | +1.5% | +6.1% | +1.6% | -0.1% | — |
| May 13, 2025 | AMC | -0.37 | 1.90 | +613.5% | 8.93 | -2.5% | +0.7% | +7.1% | +1.4% | +0.7% | +2.2% | — |
| Mar 18, 2025 | AMC | -0.51 | -0.18 | +64.7% | 8.87 | +0.9% | -6.9% | +0.8% | -2.2% | +1.7% | -6.6% | — |
| Nov 5, 2024 | AMC | -0.52 | -0.47 | +9.6% | 13.05 | +5.0% | +1.5% | +0.2% | +4.6% | -0.5% | -1.4% | — |
| Aug 7, 2024 | AMC | -0.57 | -0.46 | +19.3% | 13.71 | +3.9% | +3.1% | +2.0% | +0.2% | -1.9% | -1.4% | — |
| May 6, 2024 | AMC | -0.60 | -0.57 | +5.0% | 11.87 | +0.1% | +0.6% | -2.8% | +3.5% | -4.4% | +0.6% | — |
| Mar 25, 2024 | AMC | -0.62 | -0.60 | +3.2% | 6.50 | +70.3% | +58.3% | +37.7% | -4.7% | -0.1% | -3.0% | — |
| Nov 7, 2023 | AMC | -0.65 | -0.55 | +15.4% | 4.85 | +0.0% | -4.9% | -1.7% | -6.0% | +0.2% | +10.3% | — |
| Aug 7, 2023 | AMC | -0.65 | -0.69 | -6.2% | 5.85 | -2.1% | -5.1% | +0.5% | +1.8% | -4.2% | +0.4% | — |
| May 4, 2023 | AMC | -0.70 | -0.53 | +24.3% | 10.72 | +0.5% | +11.5% | +0.8% | +1.0% | -4.2% | -1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $33.19 | $34.10 | +2.7% | +1.0% | -0.3% | -3.7% | +5.0% | -0.3% |
| Mar 19 | BTIG | Maintains | Buy → Buy | — | $31.02 | $29.99 | -3.3% | +7.0% | +1.0% | -0.3% | -3.7% | +5.0% |
| Mar 18 | Wedbush | Maintains | Outperform → Outperform | — | $32.87 | $32.85 | -0.1% | -5.6% | +7.0% | +1.0% | -0.3% | -3.7% |
| Mar 18 | Chardan Capital | Maintains | Buy → Buy | — | $32.87 | $32.85 | -0.1% | -5.6% | +7.0% | +1.0% | -0.3% | -3.7% |
| Mar 17 | Wedbush | Maintains | Outperform → Outperform | — | $33.96 | $32.89 | -3.2% | -3.2% | -5.6% | +7.0% | +1.0% | -0.3% |
| Mar 17 | Needham | Maintains | Buy → Buy | — | $33.96 | $32.89 | -3.2% | -3.2% | -5.6% | +7.0% | +1.0% | -0.3% |
| Jan 12 | Wedbush | Maintains | Outperform → Outperform | — | $32.85 | $27.40 | -16.6% | -10.4% | +3.9% | +1.3% | -5.5% | -2.0% |
| Jan 5 | Chardan Capital | Maintains | Buy → Buy | — | $30.90 | $30.71 | -0.6% | +5.3% | +8.2% | -0.1% | -4.2% | -2.5% |
| Jan 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $30.90 | $30.71 | -0.6% | +5.3% | +8.2% | -0.1% | -4.2% | -2.5% |
| Dec 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.39 | $33.13 | +2.3% | +1.8% | +1.9% | -2.2% | -2.8% | +0.1% |
| Nov 5 | Wedbush | Maintains | Outperform → Outperform | — | $25.34 | $21.94 | -13.4% | -9.9% | -1.5% | +1.7% | -2.1% | +12.2% |
| Nov 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $25.34 | $21.94 | -13.4% | -9.9% | -1.5% | +1.7% | -2.1% | +12.2% |
| Nov 5 | BTIG | Maintains | Buy → Buy | — | $25.34 | $21.94 | -13.4% | -9.9% | -1.5% | +1.7% | -2.1% | +12.2% |
| Nov 3 | JP Morgan | Maintains | Neutral → Neutral | — | $30.04 | $29.30 | -2.5% | -13.1% | -2.9% | -9.9% | -1.5% | +1.7% |
| Oct 13 | BTIG | Maintains | Buy → Buy | — | $30.19 | $30.18 | -0.0% | +0.5% | +15.2% | +1.9% | -4.0% | -1.9% |
| Oct 10 | Needham | Maintains | Buy → Buy | — | $29.90 | $30.95 | +3.5% | +1.0% | +0.5% | +15.2% | +1.9% | -4.0% |
| Aug 13 | Chardan Capital | Maintains | Buy → Buy | — | $13.53 | $14.89 | +10.1% | +25.0% | +1.5% | +6.1% | +1.6% | -0.1% |
| Aug 13 | Wedbush | Maintains | Outperform → Outperform | — | $13.53 | $14.89 | +10.1% | +25.0% | +1.5% | +6.1% | +1.6% | -0.1% |
| Jul 1 | Needham | Maintains | Buy → Buy | — | $11.35 | $11.25 | -0.9% | +2.6% | -0.9% | -0.6% | +1.8% | +2.7% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.93 | $8.71 | -2.5% | +0.7% | +7.1% | +1.4% | +0.7% | +2.2% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $5.90 | $5.76 | -2.4% | +9.0% | +1.4% | +7.7% | +7.7% | +2.5% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.87 | $8.95 | +0.9% | -6.9% | +0.8% | -2.2% | +1.7% | -6.6% |
| Mar 19 | Chardan Capital | Maintains | Buy → Buy | — | $8.87 | $8.95 | +0.9% | -6.9% | +0.8% | -2.2% | +1.7% | -6.6% |
| Mar 18 | Needham | Maintains | Buy → Buy | — | $9.00 | $8.63 | -4.1% | -1.4% | -6.9% | +0.8% | -2.2% | +1.7% |
| Feb 19 | Chardan Capital | Maintains | Buy → Buy | — | $9.71 | $9.80 | +0.9% | -4.2% | -6.0% | -4.7% | +2.0% | -2.9% |
| Feb 18 | Needham | Maintains | Buy → Buy | — | $10.68 | $10.80 | +1.1% | -9.1% | -4.2% | -6.0% | -4.7% | +2.0% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.68 | $10.80 | +1.1% | -9.1% | -4.2% | -6.0% | -4.7% | +2.0% |
| Jan 8 | Needham | Maintains | Buy → Buy | — | $9.31 | $9.54 | +2.5% | -3.8% | +0.4% | -0.9% | -2.7% | +9.3% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.31 | $9.54 | +2.5% | -3.8% | +0.4% | -0.9% | -2.7% | +9.3% |
| Dec 10 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $13.76 | $13.89 | +0.9% | -3.6% | -2.1% | -5.1% | -2.1% | +1.5% |
| Nov 6 | Needham | Maintains | Buy → Buy | — | $13.05 | $13.70 | +5.0% | +1.5% | +0.2% | +4.6% | -0.5% | -1.4% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.05 | $13.70 | +5.0% | +1.5% | +0.2% | +4.6% | -0.5% | -1.4% |
| Sep 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.92 | $15.84 | -0.5% | -7.4% | -7.0% | +5.5% | +1.7% | +2.7% |
| Aug 8 | Needham | Maintains | Buy → Buy | — | $13.71 | $14.24 | +3.9% | +3.1% | +2.0% | +0.2% | -1.9% | -1.4% |
| Jul 11 | Wedbush | Maintains | Outperform → Outperform | — | $13.26 | $13.71 | +3.4% | +5.8% | +1.6% | +2.3% | +1.1% | -7.2% |
| Jun 28 | Needham | Maintains | Buy → Buy | — | $13.31 | $13.60 | +2.2% | +1.5% | +2.7% | -7.5% | -1.2% | +3.6% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.87 | $11.88 | +0.1% | +0.6% | -2.8% | +3.5% | -4.4% | +0.6% |
| May 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.87 | $11.88 | +0.1% | +0.6% | -2.8% | +3.5% | -4.4% | +0.6% |
| May 6 | Needham | Maintains | Buy → Buy | — | $12.02 | $12.02 | +0.0% | -1.2% | +0.6% | -2.8% | +3.5% | -4.4% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $12.76 | $12.88 | +0.9% | +5.8% | -5.4% | -4.4% | +2.0% | -5.9% |
| Mar 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.50 | $11.07 | +70.3% | +58.3% | +37.7% | -4.7% | -0.1% | -3.0% |
| Mar 26 | Needham | Maintains | Buy → Buy | — | $6.50 | $11.07 | +70.3% | +58.3% | +37.7% | -4.7% | -0.1% | -3.0% |
| Mar 26 | JP Morgan | Maintains | Neutral → Neutral | — | $6.50 | $11.07 | +70.3% | +58.3% | +37.7% | -4.7% | -0.1% | -3.0% |
| Mar 26 | Wedbush | Maintains | Outperform → Outperform | — | $6.50 | $11.07 | +70.3% | +58.3% | +37.7% | -4.7% | -0.1% | -3.0% |
| Mar 26 | TD Cowen | Upgrade | Hold → Buy | — | $6.50 | $11.07 | +70.3% | +58.3% | +37.7% | -4.7% | -0.1% | -3.0% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.50 | $11.07 | +70.3% | +58.3% | +37.7% | -4.7% | -0.1% | -3.0% |
| Feb 16 | Needham | Maintains | Buy → Buy | — | $5.31 | $5.24 | -1.3% | -0.8% | +2.1% | -0.4% | -0.7% | +11.7% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $4.31 | $4.31 | +0.0% | +12.5% | -4.9% | -1.7% | -6.0% | +0.2% |
| Aug 8 | Credit Suisse | Maintains | Outperform → Outperform | — | $5.85 | $5.73 | -2.1% | -5.1% | +0.5% | +1.8% | -4.2% | +0.4% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.85 | $5.73 | -2.1% | -5.1% | +0.5% | +1.8% | -4.2% | +0.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | Sell | 1,457 | $29.95 | $44K | 18,086 | — | — |
| Jun 1, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | Sell | 1,795 | $30.58 | $55K | 34,826 | +2.24% | -3.03% |
| May 1, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | Sell | 2,243 | $32.79 | $74K | 36,621 | +0.97% | -0.46% |
8-K
Unknown — 8-K Filing
Kahn's board appointment under standard compensation terms poses minimal risk, but investors should monitor whether new director expertise meaningfully strengthens governance or strategic oversight capabilities.
Apr 7
8-K · 4.01
!!! Very High
Unknown — 8-K 4.01: Auditor Change / Resignation
Stoke's auditor resignation raises red flags about potential accounting disagreements, which could indicate undisclosed financial issues and warrants immediate investor scrutiny of the company's disclosures.
Mar 27
8-K
Stoke Therapeutics, Inc. -- 8-K Filing
I cannot provide a meaningful investor analysis from this filing, as the summary contains only technical SEC schema metadata rather than substantive business information about Stoke Therapeutics.
Mar 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 7,092,316 | $225M | — | Dec 2025 |
| 2 | Rtw Investments, Lp | 5,623,525 | $183M | Added | Mar 2026 |
| 3 | Fmr Llc | 5,383,666 | $175M | Reduced | Mar 2026 |
| 4 | Toronto Dominion Bank | 3,173,258 | $101M | — | Dec 2025 |
| 5 | Vanguard Capital Management Llc | 2,355,603 | $77M | New | Mar 2026 |
| 6 | Deerfield Management Company, L.p. | 1,823,500 | $59M | — | Mar 2026 |
| 7 | Janus Henderson Group Plc | 1,612,781 | $52M | New | Mar 2026 |
| 8 | Assenagon Asset Management S.a. | 907,015 | $30M | Reduced | Mar 2026 |
| 9 | Mpm Bioimpact Llc | 767,038 | $25M | — | Mar 2026 |
| 10 | Opaleye Management Inc. | 695,000 | $22M | Added | Dec 2025 |
| 11 | Bank Of America Corp /de/ | 543,095 | $18M | Added | Mar 2026 |
| 12 | Tang Capital Management Llc | 500,000 | $16M | — | Dec 2025 |
| 13 | Millennium Management | 472,141 | $15M | New | Mar 2026 |
| 14 | Vanguard Portfolio Management Llc | 462,682 | $15M | New | Mar 2026 |
| 15 | Candriam S.c.a. | 446,690 | $14M | New | Dec 2025 |
| 16 | Northern Trust Corp | 431,630 | $14M | Added | Mar 2026 |
| 17 | Artisan Partners Limited Partnership | 315,492 | $10M | New | Mar 2026 |
| 18 | Jpmorgan Chase & Co | 265,473 | $8M | Reduced | Mar 2026 |
| 19 | First Trust Advisors Lp | 163,459 | $5M | — | Mar 2026 |
| 20 | Ubs Group Ag | 158,304 | $5M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.84B
Enterprise Value
$1.55B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
2.94x
P/B
5.21x
P/S
57.23x
P/FCF
40.87x
EV/EBITDA
—
Shares Out
59.2M
Financials (TTM)
Revenue
$32.1M
Net Income
-$169.8M
EBITDA
-$164.1M
Free Cash Flow
$44.9M
Op Cash Flow
$45.6M
EPS Basic
$-0.12
EPS Diluted
$-2.83
EPS Forward
$-3.38
Gross Margin
90.4%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$418.4M
Total Liab.
$66.0M
Total Equity
$352.5M
Cash
$284.7M
LT Debt
$0
Book Value/Sh
$5.95
Debt/Equity
0.00x
Current Ratio
5.28
Quick Ratio
5.28
Returns & Growth
ROE
-1.9%
ROA
-1.7%
ROIC
-5.7%
Rev Growth YoY
+404.5%
EPS Growth YoY
+92.7%
Price Returns
2W
-1.4%
1M
-5.5%
3M
-15.1%
6M
+0.0%
12M
+224.0%
Technicals
52W High
$38.35
52W Low
$11.35
50d MA
$32.07
200d MA
$30.74
RSI (14)
50.40
ATR (14)
$1.45
Beta
1.22
Avg Volume
614K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$43.86
High
$60.00
Low
$35.00
Median
$40.00
Data updated apr 27, 2026 3:18am
· Source: financialmodelingprep.com